NO20050786L - Isosorbidmononitratblandinger og fremgangsmater for deres anvendelse - Google Patents

Isosorbidmononitratblandinger og fremgangsmater for deres anvendelse

Info

Publication number
NO20050786L
NO20050786L NO20050786A NO20050786A NO20050786L NO 20050786 L NO20050786 L NO 20050786L NO 20050786 A NO20050786 A NO 20050786A NO 20050786 A NO20050786 A NO 20050786A NO 20050786 L NO20050786 L NO 20050786L
Authority
NO
Norway
Prior art keywords
methods
ismns
ismn
reduction
therapeutically effective
Prior art date
Application number
NO20050786A
Other languages
English (en)
Norwegian (no)
Inventor
John G Devane
Paul Stark
John Kelly
Jackie Butler
Original Assignee
Biovail Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Lab Inc filed Critical Biovail Lab Inc
Publication of NO20050786L publication Critical patent/NO20050786L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20050786A 2002-08-08 2005-02-14 Isosorbidmononitratblandinger og fremgangsmater for deres anvendelse NO20050786L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/214,345 US20040029959A1 (en) 2002-08-08 2002-08-08 Isosorbide mononitrate compositions and methods of their use
PCT/IB2003/004245 WO2004014849A2 (fr) 2002-08-08 2003-08-08 Compositions de mononitrate d'isosorbide et procedes d'utilisation

Publications (1)

Publication Number Publication Date
NO20050786L true NO20050786L (no) 2005-05-03

Family

ID=31494642

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050786A NO20050786L (no) 2002-08-08 2005-02-14 Isosorbidmononitratblandinger og fremgangsmater for deres anvendelse

Country Status (10)

Country Link
US (1) US20040029959A1 (fr)
EP (1) EP1545550A4 (fr)
JP (1) JP2005535700A (fr)
AU (1) AU2003263515A1 (fr)
CA (1) CA2495071A1 (fr)
IL (1) IL166299A0 (fr)
MX (1) MXPA05001559A (fr)
NO (1) NO20050786L (fr)
PL (1) PL375274A1 (fr)
WO (1) WO2004014849A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106093247A (zh) * 2016-08-19 2016-11-09 蚌埠丰原涂山制药有限公司 一种检测单硝酸异山梨酯中乙酸乙酯残留量的方法
CN107582540B (zh) * 2017-09-19 2018-06-05 扬子江药业集团上海海尼药业有限公司 一种单硝酸异山梨酯胶囊及其制备方法
CN107802610B (zh) * 2017-11-22 2020-10-20 乐普药业股份有限公司 一种单硝酸异山梨酯缓释片及制备方法
CN112121025B (zh) * 2019-06-24 2022-05-31 翰宇药业(武汉)有限公司 一种单硝酸异山梨酯缓释片剂及其制备方法
CN110478328A (zh) * 2019-08-15 2019-11-22 仁和堂药业有限公司 单硝酸异山梨酯片的制备工艺
CN110559269A (zh) * 2019-08-15 2019-12-13 仁和堂药业有限公司 一种单硝酸异山梨酯片剂及其质量检测方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000254A (en) * 1966-04-25 1976-12-28 Schmid Laboratories, Inc. Fungimycin compositions
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
JPS578490Y2 (fr) * 1977-08-12 1982-02-18
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
CH647676A5 (fr) * 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4336243A (en) * 1980-08-11 1982-06-22 G. D. Searle & Co. Transdermal nitroglycerin pad
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
IE53703B1 (en) * 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
FR2542998B1 (fr) * 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
DE3333639A1 (de) * 1983-09-17 1985-03-28 Dynamit Nobel Ag Zubereitung von nitroestern fuer die koronartherapie
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
CA1248450A (fr) * 1984-04-05 1989-01-10 Kazuo Kigasawa Piece molle
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4767808A (en) * 1984-10-05 1988-08-30 Hercon Laboratories Corporation Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant
US4681584A (en) * 1985-05-03 1987-07-21 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4655766A (en) * 1985-08-01 1987-04-07 Alza Corporation Fluid imbibing pump with self-regulating skin patch
US4698062A (en) * 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
US4826688A (en) * 1985-11-13 1989-05-02 501 Elan Corporation PLC. Controlled absorption pharmaceutical formulation
US5141752A (en) * 1986-05-09 1992-08-25 Alza Corporation Delayed drug delivery device
ES2028074T3 (es) * 1986-06-13 1992-07-01 Alza Corporation Activacion por humedad de un sistema de suministro transdermico de farmacos.
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
ATE71293T1 (de) * 1986-09-18 1992-01-15 London Pharmacy Innovation Arzneiformulierung.
CH672888A5 (fr) * 1986-11-07 1990-01-15 Mepha Ag
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5071656A (en) * 1987-03-05 1991-12-10 Alza Corporation Delayed onset transdermal delivery device
US4956181A (en) * 1987-05-08 1990-09-11 Eastman Kodak Nitrate therapy for angina pectoris
EP0290262A3 (fr) * 1987-05-08 1990-12-12 EASTMAN KODAK COMPANY (a New Jersey corporation) Thérapie de l'angine de poitrine par le nitrate
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
JPH11501026A (ja) * 1995-02-28 1999-01-26 アストラ・アクチエボラーグ イソソルビド−5−モノナイトレートの使用
WO1998027967A1 (fr) * 1996-12-20 1998-07-02 Dumex-Alpharma A/S Comprimes enrobes a liberation controlee
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
BR9905261A (pt) * 1999-09-30 2001-07-24 Libbs Farmaceutica Ltda Uma nova associação medicamentosa de liberação programada
US7108866B1 (en) * 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
JP4696210B2 (ja) * 2000-06-07 2011-06-08 トーアエイヨー株式会社 イソソルビド‐5‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法

Also Published As

Publication number Publication date
IL166299A0 (en) 2006-01-15
MXPA05001559A (es) 2005-08-19
EP1545550A4 (fr) 2011-04-13
JP2005535700A (ja) 2005-11-24
CA2495071A1 (fr) 2004-02-19
US20040029959A1 (en) 2004-02-12
WO2004014849A3 (fr) 2004-11-11
WO2004014849A2 (fr) 2004-02-19
EP1545550A2 (fr) 2005-06-29
PL375274A1 (en) 2005-11-28
AU2003263515A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
NO20050786L (no) Isosorbidmononitratblandinger og fremgangsmater for deres anvendelse
TW283645B (fr)
NO953093D0 (no) Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler
PT1066052E (pt) Celulas estaminais mesenquimatosas para a prevencao e tratamento
WO2004078113A3 (fr) Traitement et prevention de l'obesite au moyen d'inhibiteurs de cox-2 seul ou en combinaison avec des agents d'amaigrissement
WO2005037323A3 (fr) Methode pour inhiber une signalisation de nf-kappa b et son utilisation pour traiter et pour prevenir des maladies humaines
WO2000040235A3 (fr) Traitement de l'asthme a l'aide d'inhibiteurs de mek
WO2005107793A3 (fr) Ngal pour la reduction et l'amelioration des lesions ischemiques et nephrotoxiques
IL158559A0 (en) Acne treatment
NO20051426L (no) Behandling av melanom ved reduksjon i clusterin-nivaer
WO2005044194A3 (fr) Traitement ou prevention de la neoplasie a l'aide d'un inhibiteur de la proteine hsp90
BG106461A (en) Methods and use of rapid onset of reactive serotonin inhibitors for treating sexual dysfunction
WO2003018061A1 (fr) Medicaments contenant un inhibiteur de la chymase et un inhibiteur de l'ace comme principes actifs
WO2004043456A8 (fr) Inhibiteurs d'absorption du cholesterol pour le traitement de la demyelination
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
WO2004000227A3 (fr) Utilisation de derives de thio-oxindole dans le traitement de troubles cutanes
HK1099918A1 (en) Composition and use for prevention or treatment of stomatitis
WO2002056837A3 (fr) Inhibition de proteines phosphatases dans le traitement de l'insuffisance cardiaque
WO2002028433A3 (fr) Medicaments
BR0308396A (pt) Processo de tratamento de diabetes mellitus incluindo condições associadas com diabetes mellitus e complicações de diabetes mellitus
EP1610814B8 (fr) Compositions therapeutiques pour pathologies auto-immunes
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
WO1996000068A3 (fr) Therapie combinee contre les infections a vih
WO2004012732A3 (fr) Utilisation d'un inhibiteur du proteasome dans le traitement du dysfonctionnement endothelial et/ou dans le cadre d'une therapie a base de proteasome a faible dose

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application